B
BLU

Braidwell’s BELLUS Health Inc. BLU Stock Holding History

Braidwell’s Portfolio BLU Stock Details BLU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,126,194
Closed -$29.7M – 95
2023
Q1 		$29.7M Buy
4,126,194
+13,700
+0.3% +$106K 0.98% 39
2022
Q4 		$33.8M Buy
+4,112,494
New +$38.3M 1.13% 32

Other funds holding BLU

CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
VAM
Vazirani Asset Management New York $20.3M AUM 79.33% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $449M AUM 51.52% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
SAM
Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return
Canada Life
Canada Life Winnipeg, Manitoba, Canada $62.7B AUM 37.65% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Braidwell's BLU Position: Q2 2023 in Review

Braidwell sold out of BELLUS Health Inc. (BLU) in Q2 2023, closing a stake of 4,126,194 shares — an estimated $29.7M sold.

Braidwell first reported a position in BLU in Q4 2022 and held it in 2 quarters. The position peaked at $33.8M in Q4 2022. 11 funds tracked by Wall St. Rank hold BLU as of Q2 2023.

  • Braidwell reported no remaining BELLUS Health Inc. position as of Q2 2023 after selling out during the quarter.
  • Braidwell sold 4,126,194 BELLUS Health Inc. shares in Q2 2023, an estimated $29.7M.
  • Braidwell first reported a position in BELLUS Health Inc. in Q4 2022 and held it in 2 quarters.
  • Braidwell's BELLUS Health Inc. position peaked at $33.8M in Q4 2022.
  • 11 funds tracked by Wall St. Rank held BELLUS Health Inc. as of Q2 2023.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.